echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Clin Gastroenterology H: Peak concentrations of Usnu monoantigen resistance were associated with endoscopic and bio-chemical remission in patients with Crohn's disease

    Clin Gastroenterology H: Peak concentrations of Usnu monoantigen resistance were associated with endoscopic and bio-chemical remission in patients with Crohn's disease

    • Last Update: 2021-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The 2019 European Crohn's Colitis Organization recommends using using us as a first-line biological agent for the treatment of moderate to severe Crohn's disease.
    with the new mechanism of white methicillin, Usnu monoantigen has the characteristics of rapid effectiveness and continuous maintenance of remission.
    the approval of usmano monotherapy marks an important progress in the treatment of Crohn's disease in China, and also provides a brand-new treatment for crohn's disease patients in China, especially those with moderate to severe diseases.
    But the relationship between peak concentrations of the drug during the first two weeks of use and disease prognosis is not yet known, and the study aims to assess the relationship between the serum concentration of usthabyn resistance during the two-week treatment and endoscopic and bio-chemical remission in patients with CD.
    In this forward-looking observational study, due to endoscopic markers of active CDs, the researchers measured the concentration of Usnu monoantigen in serums in 41 consecutive patients with using Usnu monoantigen (using dose of Usnu monoantigen: 6 mg / kg, intravenously, and then 90 mg every 8 weeks).
    researchers measured the exposure of usanut monoantigen (peak concentration immediately after intravenous infusion, concentration in week 2, and curve area from week 2 to week 2).
    we investigated the correlation between these parameters and endoscopic mitigation.
    results showed that 10 patients (24.4%) achieved endoscopic remission in week 24, 17 patients (41.5%) reached biological index remission in week 8, 17 patients (41.5%) reached biological remission in week 16, and 21 patients (51.2%) reached biological remission in week 24.
    the peak concentration associated with endoscopic mitigation was AAUC: 0.717; (95% CI, 0.517-0.916);
    , the researchers in this study determined that serum concentrations as early as 1 hour after intravenous infusion can be used to predict CD patients who are most likely to achieve endoscopic remission (the higher the better).
    this early measurement can be used to optimize the treatment of CD.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.